CJC-1295 (without DAC) and Vesilute Interaction

Synergistic
Mechanism-based 47% confidence

CJC-1295 (without DAC) and Vesilute have a synergistic interaction with 47% confidence. CJC-1295 (without DAC) and Vesilute work through complementary pathways. Growth hormone signaling supports tissue repair processes. A well-established combination in recovery protocols. These compounds primarily affect different organ systems.

Compound Profiles

CJC-1295 (without DAC)

Short-Acting Growth Hormone Releasing Hormone Analog

Binds GHRH receptors on somatotroph cells in the pituitary gland, stimulating cAMP production and physiological GH pulses. The brief 30-minute half-life allows pulsatile release versus prolonged elevation.

Half-life: 30 minutes - 2 hours Typical dose: 100-300mcg per injection growth hormone, weight loss
ghrh receptor carcinogenic riskestrogenicinsulin disruptingteratogenic
View full profile

Vesilute

ED Dipeptide | Bladder & Urinary Tract Bioregulator

Vesilute acts on the smooth muscle cells and vascular endothelium of the urogenital system. It is proposed to: (1) regulate smooth muscle contraction and relaxation in the bladder wall, (2) enhance microcirculation and blood flow in pelvic tissues including prostate, (3) support cellular regeneration and tissue repair in the urinary tract, (4) reduce hyperemia and inflammation-related dysfunction, and (5) modulate gene expression related to urogenital tissue homeostasis through bioregulation pathways characteristic of Khavinson peptides.

Half-life: Not established Typical dose: 10-20 mg per day other, longevity
carcinogenic riskteratogenic
View full profile

Combined Organ Load

GI Tract
low
Pituitary
low

Shared Safety Flags

2x 2 compounds share the carcinogenic-risk safety flag (CJC-1295 (without DAC), Vesilute). Monitor accordingly.
2x 2 compounds share the teratogenic safety flag (CJC-1295 (without DAC), Vesilute). Monitor accordingly.

Frequently Asked Questions

Can I take CJC-1295 (without DAC) with Vesilute?

Yes, CJC-1295 (without DAC) and Vesilute can generally be taken together. CJC-1295 (without DAC) and Vesilute work through complementary pathways. Growth hormone signaling supports tissue repair processes. A well-established combination in recovery protocols.

Is CJC-1295 (without DAC) and Vesilute safe together?

Based on pharmacological analysis, this combination is considered synergistic. However, shared safety flags include: carcinogenic risk, teratogenic. Monitor accordingly.

What are the interactions between CJC-1295 (without DAC) and Vesilute?

CJC-1295 (without DAC) and Vesilute work through complementary pathways. Growth hormone signaling supports tissue repair processes. A well-established combination in recovery protocols. This assessment has 47% confidence and is inferred from pharmacological mechanism analysis.

How should I time CJC-1295 (without DAC) and Vesilute?

CJC-1295 (without DAC) has a half-life of 30 minutes - 2 hours and Vesilute has a half-life of Not established. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

Check this pair in the full Interaction Checker Full comparison: CJC-1295 (without DAC) vs Vesilute

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.